IHL - INCANNEX - HOLDERS RESEARCH, page-931

First 931 Last

Share
Profile

Follow
Doggo04

514 Posts.

88

06/09/23

10:02

Post #: 69748887
Share

Originally posted by rusty02: ↑

Totally agree.
We just need to get this Redomicile D&D out of the way and move on. New trading platform with OOS not ADR, zero selling pressure with a much wider/larger investment audience and a huge market IND for mental health, inflammation and OSA. Combine this with a way oversold equity in a health care listing that presents sound 28 pathways, highly recognised team, COH to accomplish short term benchmarks, PSI-GAD clinic cashflow short term with 2 pathways entering phase 2/3 trials and short term commercialisation of our gum asset.

IMO once on the NASDAQ the selling pressure in IHL we are experiencing now will be a distant memory in IXHL where focus will be on near term potential. IHL 42X FDA approval deriskd this pathway in a massive scale that has been overlooked by the ASX's fixation on Redomicile up. Everyone I speak to regarding IHL 42X look forward to the day where they have access to a simple administered tablet that could enhance their deep sleep by 50%. I look at this period before listing as the last buying opportunity. The potential here is in the next 12-18 months is massive and it begins with a yes vote in roughly 6 weeks. My vote is a yes.
GLAH

Expand

I think everyone is overlooking one massive problem with 42x.

Once we are all sleeping soundly overnight after using 42x, we won't be awake to trade or monitor Nasdaq market action.

All jokes aside gltah.

IHL Price at posting: 7.6¢ Sentiment: Hold Disclosure: Held
12 Upvote

0 Great analysis

Reply

Top Stories

Quit before you're fired: Russia bans uranium exports to USA, duplicating extant US ban

PNN

Power gets set for 1000-metre maiden drilling program in Brazil

US election outcomes: Key economic and market takeaways

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing